Cramer’s Investing Club Stock Profile: Drugmaker Abbvie deserves a



As we wait for the market to gain more appreciation for Abbvie, the roughly 4.15% dividend handsomely pays us for our patience.



Read More: Cramer’s Investing Club Stock Profile: Drugmaker Abbvie deserves a
Abbott LaboratoriesAbbVieAbbvie IncBiotech and PharmaceuticalsBreaking News: Marketsbusiness newsclubCramersdeservesdrugmakerHealth care industryinvestingInvestment strategyJIM CRAMERMarketsprofilestock
Comments (0)
Add Comment